1GILD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$67.18 |
52 Week High | US$81.64 |
52 Week Low | US$65.52 |
Beta | 0.20 |
1 Month Change | 0% |
3 Month Change | -8.37% |
1 Year Change | -9.87% |
3 Year Change | 18.84% |
5 Year Change | 12.91% |
Change since IPO | -2.00% |
Recent News & Updates
Recent updates
Shareholder Returns
1GILD | IT Biotechs | IT Market | |
---|---|---|---|
7D | -0.9% | 4.3% | 1.3% |
1Y | -9.9% | -2.7% | 25.2% |
Return vs Industry: 1GILD underperformed the Italian Biotechs industry which returned -1.1% over the past year.
Return vs Market: 1GILD underperformed the Italian Market which returned 26.4% over the past year.
Price Volatility
1GILD volatility | |
---|---|
1GILD Average Weekly Movement | 4.0% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 4.2% |
10% most volatile stocks in IT Market | 7.8% |
10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: 1GILD has not had significant price volatility in the past 3 months.
Volatility Over Time: 1GILD's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 18,000 | Dan O'Day | https://www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
1GILD fundamental statistics | |
---|---|
Market cap | €84.33b |
Earnings (TTM) | €5.25b |
Revenue (TTM) | €25.14b |
16.1x
P/E Ratio3.4x
P/S RatioIs 1GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1GILD income statement (TTM) | |
---|---|
Revenue | US$27.12b |
Cost of Revenue | US$6.02b |
Gross Profit | US$21.10b |
Other Expenses | US$15.43b |
Earnings | US$5.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 4.55 |
Gross Margin | 77.80% |
Net Profit Margin | 20.89% |
Debt/Equity Ratio | 109.8% |
How did 1GILD perform over the long term?
See historical performance and comparison